Clinical Trial

Checkpoint Inhibitor-induced Liver Injury

Study acronym: ChILI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and histological features associated with it.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-07-14; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Recruiting 2021-04-27
Trial Details
NCT Number NCT04476563
Lead Sponsor University of Nottingham
Collaborators: Pfizer
Conditions Immune-Mediated Hepatitis
Enrollment 160 participants
Start Date 2020-10-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-24